Pacific Biosciences Of California (PACB) Net Margin (2010 - 2026)

Pacific Biosciences Of California's Net Margin history runs 17 years deep, the most recent figure standing at 22.26% for Q1 2026.

• In Q1 2026, Net Margin rose 112455.0% year-over-year to 22.26%; the TTM figure through Mar 2026 stood at 80.34% (up 35137.0% YoY), while the FY2025 annual figure was 341.47%, down 14029.0% from the prior year.
• Net Margin was 22.26% for Q1 2026 at Pacific Biosciences Of California, up from 90.43% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 6.04% in Q4 2024 to a low of 1146.81% in Q1 2025.
• Historically, Net Margin has averaged 230.57% across 5 years, with a median of 151.94% in 2024.
• The sharpest annual moves came in 2025 and 2026: Net Margin plunged 94537 bps in 2025, then soared 112455 bps in 2026.
• A 5-year view of Net Margin shows it stood at 308.5% in 2022, then jumped by 54 bps to 140.55% in 2023, then surged by 104 bps to 6.04% in 2024, then sank by 1596 bps to 90.43% in 2025, then surged by 75 bps to 22.26% in 2026.
• The last three Net Margin figures came in at 22.26% (Q1 2026), 90.43% (Q4 2025), and 98.85% (Q3 2025), per Business Quant data.